Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMX-1002
- Development stage
- Unknown
- Lead developer
- DemeRx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DMX-1002 is an oral formulation of ibogaine, a naturally occurring psychedelic product isolated from a West African shrub. It is being developed as a potential treatment for opioid use disorder (OUD). The compound acts as a cholinergic, glutamatergic, and monoaminergic receptor modulator. In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the potential to be a disease-modifying treatment for patients seeking to end their cycle of drug dependence.
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)AChR (Acetylcholine receptor)GluR (Glutamate receptors)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on DMX-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMX-1002.